Catalent signs anti-cancer development deal with Pure MHC
Catalent will develop a humanised version of RL21A antibody and engineer a cell line
Catalent Pharma Solutions has signed a product development agreement with Pure MHC, an Austin, Texas-based provider of MHC-based diagnostics and therapeutics.
Under the terms of the agreement, Catalent will develop a humanised version of Pure MHC’s proprietary RL21A antibody and engineer a cell line to express the antibody using Catalent’s GPEx technology.
Somerset, NJ-based Catalent will subsequently produce purified monoclonal antibodies to support Pure MHC’s preclinical development in preparation for clinical trials with humanised RL21A for the treatment of cancer.
GPEx technology is used to generate mammalian cells with high yields and stability, helping to speed drugs to clinic.
